☆Versant Venture Management, LLC
Quality Q
0.770
AUM ($M)
163
Positions
8
Turnover
0.11
Top-10 wt
100%
Herfindahl
0.290
History (qtrs)
6
Excess Return
-109.7%
AI Eval Run AI Eval
Holdings · 8 positions · portfolio value $163M
| Ticker | Name | Activity | Security Type | Weight | Δ Weight | Value ($M) | Shares | Δ Shares | Qtrs Held | Excess Return |
|---|---|---|---|---|---|---|---|---|---|---|
| ☆GLUE funds › | Monte Rosa Therapeutics, Inc. | HOLD | — | 47.3% | +10.3% | 77.0 | 3,180,780 | +0 | 5 | — |
| ☆IPSC funds › | Century Therapeutics, Inc. | HOLD | — | 18.3% | -1.1% | 29.8 | 12,166,109 | +0 | 2 | — |
| ☆JBIO funds › | Jade Biosciences, Inc. | TRIM | Common Stock | 13.6% | -1.6% | 22.0 | 991,783 | -534,037 | 5 | — |
| ☆LENZ funds › | Lenz Therapeutics, Inc. | HOLD | — | 9.3% | -7.9% | 15.1 | 2,656,888 | +0 | 4 | -109.7% |
| ☆CTNM funds › | Contineum Therapeutics, Inc. | HOLD | — | 5.5% | +0.5% | 8.9 | 542,628 | +0 | 5 | — |
| ☆CRSP funds › | CRISPR Therapeutics AG | HOLD | — | 5.0% | -0.0% | 8.1 | 148,831 | +0 | 5 | — |
| ☆SKYE funds › | Skye Bioscience, Inc. | HOLD | — | 0.9% | -0.0% | 1.4 | 2,007,704 | +0 | 5 | — |
| ☆CUSIP:87978U108 funds › | Tempest Therapeutics, Inc. | HOLD | — | 0.2% | -0.1% | 0.3 | 269,772 | +0 | 5 | — |
Point-in-time history
| Period | AUM ($M) | Positions | Turnover | Top-10 wt | Herfindahl | Quality Q | Skill | Universe |
|---|---|---|---|---|---|---|---|---|
| 2026Q2 | 163 | 8 | 0.11 | 100% | 0.290 | 0.770 | — | in |
| 2026Q1 | 141 | 8 | 0.20 | 100% | 0.232 | 0.587 | — | in |
| 2025Q4 | 151 | 7 | 0.37 | 100% | 0.315 | 0.229 | — | in |
| 2025Q3 | 212 | 9 | 0.59 | 100% | 0.387 | 0.057 | — | in |
| 2025Q2 | 82 | 8 | 0.27 | 100% | 0.232 | 0.353 | — | entered |
| 2025Q1 | 60 | 7 | 0.00 | 100% | 0.288 | 0.000 | — | out |
Long US-equity 13F disclosures only · up to 45-day reporting lag · sells = reduce/avoid, not short.
JSON: /api/signals ·
/api/funds ·
/api/status